Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 121

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 121
---
 to support further development.

<div align='center'>78</div>

Competition

The pharmaceutical industry
is characterized by rapidly advancing technologies and intense competition and a strong emphasis on proprietary drugs. While we believe
that our knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many
different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental
agencies, as well as public and private research institutions. Any product candidates that we successfully develop and commercialize,
if approved, will compete with existing therapies and new therapies that may become available in the future.

The key competitive
factors affecting the success of all of our product candidates, if approved, are likely to be their safety, efficacy, convenience, price,
the level of generic competition, the existence of therapeutic alternatives and the availability of coverage and reimbursement from government
and other third-party payors.

Many of our competitors
have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting
clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical
and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller
or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and
established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel
and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary
to, or necessary for, our programs. The current market for treatments that assist in novel therapeutics for major unmet medical needs,
is highly unknown. Our commercial opportunity would be reduced significantly if our competitors develop and commercialize products that
are safer, more effective, more convenient, have fewer side effects or are less expensive than our product candidates.

Competition related to Nano Mupirocin

The global challenge of antibiotic resistance
has prompted significant efforts by pharmaceutical companies, biotechnology firms, and academic institutions to develop innovative therapeutic
solutions, including novel antibiotics, antibiotic combination therapies, bacteriophage therapies, antimicrobial peptides, and other
non-traditional antibacterial strategies. Our Nano-Mupirocin product candidate is being evaluated as a potential systemic therapy that
leverages the known antibacterial activity of mupirocin together with a novel liposomal delivery system. This approach may allow alternative
distribution and pharmacokinetic properties in preclinical models; however, this